Clinical trials: CAR-T
Multiple Myeloma
Efficacy and Safety Evaluation of BCMA-UCART
This trial aims to evaluate the safety and efficacy of BCMA-UCART in treating patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT03752541
- Testing
- BCMA-UCART
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bioray Laboratories
Leukemia, B-cell
INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia
This study, a single-center, open, single-dose clinical study, was designed to evaluate the safety, tolerability, and pharmacokinetic profile of INS19 CAR-T cells for the treatment of patients with relapsed or refractory acute B…
- Trial name
- NCT06209671
- Testing
- INS19 CAR-T Cells
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
Peritoneal Carcinomatosis, Peritoneal Metastases
CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
This is an open-label, dose-escalation, phase I trial of the safety and efficacy of anti-CEA intraperitoneal CAR-T infusions for treatment in patients with CEA-expressing adenocarcinoma peritoneal metastases or malignant ascites.
- Conditions
- Peritoneal Carcinomatosis, Peritoneal Metastases, Colorectal Cancer, Gastric Cancer
- Trial name
- NCT03682744
- Testing
- anti-CEA CAR-T cells
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sorrento Therapeutics, Inc.